Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

被引：1
|
作者：
Bishnoi, S. [1 ]
Cosman, R. [2 ]
Moore, M. [3 ]
Eek, R. [4 ]
Mant, A. [5 ]
Zielinski, R. [6 ]
Chan, L. S. [7 ]
Ma, Y. [8 ]
Zhang, Q. [9 ]
Yau, T. [10 ]
Aghmesheh, M. [11 ]
Tse, A. N. [9 ]
机构：
[1] Ashford Canc Ctr Res, Dept Med Oncol, Adelaide, SA, Australia
[2] St Vincents Hosp, Dept Med Oncol, Sydney, NSW, Australia
[3] Alfred Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[4] Border Med Oncol, Dept Med Oncol, Albury, NSW, Australia
[5] Box Hill Hosp, Dept Oncol, Melbourne, Vic, Australia
[6] Orange Hlth Serv, Oncol Unit, Orange, NSW, Australia
[7] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[8] CStone Pharmaceut Su Zhou Co Ltd, Clin Dept, Suzhou, Peoples R China
[9] CStone Pharmaceut Suzhou Co Ltd, Translat Med & Early Dev, Suzhou, Peoples R China
[10] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[11] Southern Mediacal Day Care Ctr, Dept Med Oncol, Wollongong, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1365
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
981P
引用
收藏
页码：S840 / S840
页数：1
相关论文
共 50 条
  • [21] Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.
    Wen, Xizhi
    Zhang, Xiaoshi
    Ding, Ya
    Li, Dandan
    Li, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Coward, Jermaine
    Abed, Afaf
    Nagrial, Adnan
    Markman, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
    Patnaik, Amita
    Kang, Soonmo Peter
    Tolcher, Anthony W.
    Rasco, Drew Warren
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Perez, Crystal
    Gergich, Kevin
    Lehnert, Manfred
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
    Umeda, Yoshiyasu
    Yoshikawa, Shusuke
    Kiniwa, Yukiko
    Maekawa, Takeo
    Yamasaki, Osamu
    Isei, Taiki
    Matsushita, Shigeto
    Nomura, Motoo
    Nakai, Yasuo
    Fukushima, Satoshi
    Saito, Shintaro
    Takenouchi, Tatsuya
    Tanaka, Ryo
    Kato, Hiroshi
    Otsuka, Atsushi
    Matsuya, Taisuke
    Baba, Natsuki
    Nagase, Kotaro
    Inozume, Takashi
    Onuma, Takehiro
    Kuwatsuka, Yutaka
    Fujimoto, Noriki
    Kaneko, Takahide
    Onishi, Masazumi
    Namikawa, Kenjiro
    Yamazaki, Naoya
    Nakamura, Yasuhiro
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 361 - 372
  • [26] Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
    Perez, D. Roda
    Zugazagoitia, J.
    Garralda, E.
    Spira, A. I.
    El-Khoueiry, A. B.
    Zhao, Y.
    Oppelt, P.
    Lin, X.
    Xie, S.
    Chen, M.
    Gan, J.
    Wong, G.
    Pollard, J. Russella
    Hedrich, W.
    Pallante, J.
    Adrian, F.
    Schweizer, L.
    Shi, X.
    Andtbacka, R. H. I.
    ANNALS OF ONCOLOGY, 2024, 35 : S686 - S686
  • [27] A phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas
    Shen, L.
    Li, J.
    Xu, N.
    Xing, B.
    Zhang, Q.
    Zhao, Y.
    Cao, J.
    Ding, J.
    Wang, J.
    Wang, Y.
    Dai, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 516 - 516
  • [28] Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in first-line advanced squamous non-small cell lung cancer (sqNSCLC): Initial results from a phase Ib study.
    Zhou, Caicun
    Xiong, Anwen
    Li, Wei
    Wang, Lei
    Wu, Fengying
    Yu, Jia
    Mao, Chenyu
    Qian, Jiong
    Zheng, Yulong
    Jiang, Haiping
    Gao, Yuan
    Xiao, Cheng
    Wang, Wenxiang
    Zhuang, Wu
    Yang, Jun
    Sun, Jiya
    Wang, Hongli
    Liu, Ying
    Xu, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] A PHASE 1B/2, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF AN ANTI-CTLA-4 NEOBODYTM ADG116 IN COMBINATION WITH PEMBROLIZUMAB (ANTI-PD-1 ANTIBODY) IN PATIENTS WITH ADVANCED/ METASTATIC SOLID TUMORS: A PRELIMINARY UPDATE
    Tolcher, Anthony
    Powderly, John
    Shi, Kristine
    Zheng, Songmao
    Liu, Guizhong
    Shang, Jin
    Wang, Xinwei
    Li, Wenda
    Lowe, Dana
    Chisamore, Michael
    Luo, Peter
    Zha, Jiping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A804 - A804
12345